Opportunity Information: Apply for PAR 13 308
Apply for PAR 13 308
- The National Institutes of Health in the environment health income security and social services sector is offering a public funding opportunity titled "Developmental Pharmacology and Toxicology Role of Ontogeny (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Aug 7, 2013 and posted on Aug 5, 2013.
- Applicants must submit their applications by Sep 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) County governments For profit organizations other than small businesses Small businesses Public housing authorities/Indian housing authorities City or township governments State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Developmental Pharmacology and Toxicology Role of Ontogeny (R21) funding opportunity (PAR-13-308) is a National Institutes of Health (NIH) discretionary grant program designed to support early-stage, exploratory research in developmental pharmacology and toxicology. The central theme is ontogeny, meaning how biology changes as humans develop, and how those age-related changes affect the way drugs are absorbed, distributed, metabolized, and eliminated, as well as how drugs act on their targets and potentially cause toxicity. The FOA is aimed at multidisciplinary, investigator-initiated projects that can be basic and/or translational, with a strong emphasis on understanding developmental differences from fetal life through adolescence, especially as they relate to drug-metabolizing enzymes, drug transporters, receptors, and downstream signaling pathways.
This opportunity uses the NIH R21 mechanism, which typically supports innovative, high-risk or high-reward concepts that may still be in the earlier proof-of-concept stage. The listed award ceiling is $200,000, and there is no cost-sharing or matching requirement. The program is broadly relevant to research that can improve pediatric therapeutics and safety by clarifying why children at different developmental stages can respond differently to the same medication, why dosing cannot simply be scaled down from adult regimens, and how developmental biology can change vulnerability to adverse drug reactions or environmental toxicants. By focusing on fetal life to adolescence, the FOA aligns with the idea that critical developmental windows can shape drug response and toxicity in ways that are not seen in adults.
Eligibility is intentionally broad. In addition to standard academic institutions, eligible applicants include public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), small businesses and other for-profit organizations (other than small businesses are also explicitly included), and a wide range of government entities such as state governments, county governments, city or township governments, special district governments, and public housing authorities/Indian housing authorities. The announcement also specifies eligibility for Tribal governments and Tribal organizations, including Federally recognized Tribes and other Tribal entities, as well as institutions that serve specific populations (for example, HBCUs, Hispanic-serving institutions, AANAPISI institutions, and Tribally Controlled Colleges and Universities). Importantly, non-U.S. entities are eligible to apply, including foreign organizations and foreign institutions, and non-U.S. components of U.S. organizations are also eligible; foreign components are allowed consistent with NIH policy.
Administratively, this FOA was posted on August 5, 2013 (created August 7, 2013) and had an original and current closing date of September 7, 2016, with an archive date of October 8, 2016, indicating it is no longer active as a current competition but remains available as a reference. The program falls under the broader activity categories of environment, health, income security, and social services, and it is associated with CFDA numbers 93.113 (Environmental Health) and 93.865 (Child Health and Human Development Extramural Research), reflecting its cross-cutting relevance to both pediatric development and environmental/toxicological health questions.
In practical terms, the FOA is seeking projects that explain developmental changes in the biological systems that determine drug exposure and drug effects. That can include work characterizing how enzyme expression or activity changes with age, how transporters in tissues like liver, intestine, kidney, and brain mature over time, how receptor levels or receptor sensitivity shift across childhood development, and how signaling networks evolve in ways that alter therapeutic response or toxicity risk. The emphasis on multidisciplinary approaches suggests NIH was encouraging collaborations across pharmacology, toxicology, pediatrics, developmental biology, genetics/genomics, systems biology, modeling and simulation, and clinical translation, with the goal of building a stronger evidence base for safer and more effective therapies for fetuses, infants, children, and adolescents.
The full announcement was made available through the NIH grants guide page (http://grants.nih.gov/grants/guide/pa-files/PAR-13-308.html). For technical issues accessing the announcement or linking problems, the FOA lists the NIH Office of Extramural Research (OER) Webmaster contact (FBOWebmaster@OD.NIH.GOV).
FAQs: Developmental Pharmacology and Toxicology Role of Ontogeny (R21) (PAR-13-308)
What is the Developmental Pharmacology and Toxicology Role of Ontogeny (R21) funding opportunity?
It is a National Institutes of Health (NIH) discretionary grant program (FOA: PAR-13-308) that supports early-stage, exploratory research in developmental pharmacology and toxicology. The focus is on ontogeny (how biology changes as humans develop) and how those developmental changes influence drug exposure, drug action, and toxicity from fetal life through adolescence.
What does "ontogeny" mean in the context of this FOA?
Ontogeny refers to age-related biological changes that occur as humans develop. In this FOA, it specifically means developmental changes that affect how drugs are absorbed, distributed, metabolized, and eliminated, as well as how drugs interact with their targets and how toxicity can occur at different stages of development.
What is the main scientific focus of the opportunity?
The FOA emphasizes understanding developmental differences from fetal life through adolescence that shape drug response and toxicity. It targets biological systems such as drug-metabolizing enzymes, drug transporters, receptors, and downstream signaling pathways that can change across developmental stages.
What types of research projects are encouraged?
Multidisciplinary, investigator-initiated projects that can be basic and/or translational. The FOA highlights projects aimed at explaining developmental changes in biological systems that determine drug exposure and effects, including mechanisms that alter therapeutic response or toxicity risk at different ages.
Does the FOA prioritize basic research, translational research, or both?
Both. The opportunity explicitly supports projects that can be basic and/or translational, as long as they center on developmental (ontogenic) differences relevant to pharmacology and toxicology.
What developmental time period does this FOA focus on?
The FOA emphasizes development from fetal life through adolescence, highlighting that critical developmental windows can shape drug response and toxicity in ways that may not be observed in adults.
Why is this FOA relevant to pediatric therapeutics and safety?
It is intended to improve understanding of why children at different developmental stages can respond differently to the same medication, why dosing cannot simply be scaled down from adult regimens, and how developmental biology can change vulnerability to adverse drug reactions or environmental toxicants.
What kinds of biological mechanisms are specifically called out?
The FOA calls out developmental differences related to drug-metabolizing enzymes, drug transporters, receptors, and downstream signaling pathways. It also notes practical examples such as age-related maturation of transporters in tissues like liver, intestine, kidney, and brain; changes in enzyme expression or activity; and shifts in receptor levels or sensitivity across development.
What grant mechanism is used for this opportunity?
This FOA uses the NIH R21 mechanism, which is typically intended for innovative, high-risk/high-reward research that may be at an early, proof-of-concept stage.
What is the award ceiling for this R21 opportunity?
The listed award ceiling is $200,000.
Is cost-sharing or matching required?
No. The FOA states there is no cost-sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include academic institutions; public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); small businesses; other for-profit organizations (including those other than small businesses); and many government entities (state, county, city or township, special district governments, and public housing authorities/Indian housing authorities).
Are Tribal governments and Tribal organizations eligible?
Yes. The FOA specifies eligibility for Tribal governments and Tribal organizations, including Federally recognized Tribes and other Tribal entities.
Are institutions serving specific populations included in eligibility?
Yes. The FOA explicitly includes institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, AANAPISI institutions, and Tribally Controlled Colleges and Universities.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The FOA states that non-U.S. entities are eligible, including foreign organizations and foreign institutions. It also allows non-U.S. components of U.S. organizations, and foreign components are permitted consistent with NIH policy.
Is this funding opportunity still active?
No. The FOA indicates an original and current closing date of September 7, 2016, and an archive date of October 8, 2016. This means it is no longer an active competition, but it remains available as a reference.
When was the FOA posted and created?
The FOA was posted on August 5, 2013, and created on August 7, 2013.
What are the activity categories associated with this program?
The FOA is associated with broader activity categories including environment, health, income security, and social services.
Which CFDA numbers are associated with this opportunity?
The FOA is associated with CFDA 93.113 (Environmental Health) and 93.865 (Child Health and Human Development Extramural Research), reflecting relevance to both environmental/toxicological health and child development research.
Where can the full NIH announcement be found?
The full announcement is available through the NIH Grants Guide page at: http://grants.nih.gov/grants/guide/pa-files/PAR-13-308.html
Who should be contacted for technical issues accessing the announcement or link problems?
For technical issues or linking problems, the FOA lists the NIH Office of Extramural Research (OER) Webmaster contact: FBOWebmaster@OD.NIH.GOV
Browse more opportunities from the same category: Environment Health Income Security and Social Services
Next opportunity: Developmental Pharmacology and Toxicology Role of Ontogeny (R03)
Previous opportunity: Tribal Transportation Program Safety Funds
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 308
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 308) also looked into and applied for these:
| Funding Opportunity |
|---|
| Developmental Pharmacology and Toxicology Role of Ontogeny (R03) Apply for PAR 13 307 Funding Number: PAR 13 307 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $50,000 |
| Developmental Pharmacology and Toxicology Role of Ontogeny (R01) Apply for PAR 13 306 Funding Number: PAR 13 306 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Environmental Contributors to Autism Spectrum Disorders (R01) Apply for PAR 14 203 Funding Number: PAR 14 203 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $400,000 |
| Environmental Contributors to Autism Spectrum Disorders (R21) Apply for PAR 14 202 Funding Number: PAR 14 202 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Centers of Excellence on Environmental Health Disparities Research (P50) Apply for RFA ES 14 010 Funding Number: RFA ES 14 010 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $1,000,000 |
| Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54) Apply for PAR 15 146 Funding Number: PAR 15 146 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21) Apply for PAR 15 315 Funding Number: PAR 15 315 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Genetic Susceptibility and Variability of Human Structural Birth Defects (R01) Apply for PA 08 011 Funding Number: PA 08 011 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Pharmacology (R03) Apply for PAR 08 215 Funding Number: PAR 08 215 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Pharmacology (R21) Apply for PAR 08 216 Funding Number: PAR 08 216 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Genetic and Genomic Analysis of Xenopus (R01) Apply for PAR 09 240 Funding Number: PAR 09 240 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Genetic and Genomic Analysis of Xenopus (R21) Apply for PAR 09 241 Funding Number: PAR 09 241 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01) Apply for PAR 10 180 Funding Number: PAR 10 180 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54) Apply for PAR 10 181 Funding Number: PAR 10 181 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Pharmacology (R01) Apply for PAR 11 057 Funding Number: PAR 11 057 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $499,999 |
| Developmental Pharmacology (R03) Apply for PAR 11 058 Funding Number: PAR 11 058 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $50,000 |
| Developmental Pharmacology (R21) Apply for PAR 11 059 Funding Number: PAR 11 059 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01) Apply for PAR 11 155 Funding Number: PAR 11 155 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Autism Centers of Excellence Centers (P50) Apply for RFA HD 12 195 Funding Number: RFA HD 12 195 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $1,500,000 |
| Autism Centers of Excellence Networks (R01) Apply for RFA HD 12 196 Funding Number: RFA HD 12 196 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $2,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 308", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.